BBIO 23.04 (+2.22%)
US10806X1028BiotechnologyBiotechnology

BridgeBio Pharma (BBIO) Stock Highlights

23.04 | +2.22%
2024-11-21 01:44:06
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Statistics

Range Today
22.05 23.16
Volume Today 1.39M
Range 1 Year
21.62 44.32
Volume 1 Year 464.23M
Range 3 Year
4.98 44.32
Volume 3 Year 1.7B
Range 10 Year
4.98 73.5
Volume 10 Year 2.13B

Highlights

Market Capitalization 5.09B (mid)
Floating Shares 127.53M
Current Price 23.04
Price To Earnings -9.77
Price To Revenue 28.11
Earnings Per Share -2.64
Payout Ratio 0%

Performance

Latest +2.22%
1 Month -10.39%
3 Months -7.47%
6 Months -23.33%
1 Year -21.1%
3 Years -45.98%
5 Years -23.33%
10 Years -25.07%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.